Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.67 |
| ▸ | CTSD | P07339 | 3/20 | 0.67 |
| ▸ | CTSB | P07858 | 14/20 | 0.63 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3351689 | 1.00 | BACE1 (0.67) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL3172151 | 0.91 | BACE1 (0.79) | BACE1CTSDCTSB | |
| SCHEMBL3179026 | 0.91 | BACE1 (0.79) | BACE1CTSDCTSB | |
| SCHEMBL5448502 | 0.91 | BACE1 (0.67) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL5448505 | 0.91 | BACE1 (0.67) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL3354922 | 0.90 | BACE1 (0.72) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL5442012 | 0.90 | BACE1 (0.72) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL3354916 | 0.90 | BACE1 (0.72) | BACE1CTSDCTSBBACE2 | |
| SCHEMBL3349285 | 0.90 | BACE1 (0.64) | BACE1CTSD | |
| SCHEMBL3349278 | 0.90 | BACE1 (0.64) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | claimed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | BACE1 1/4885CTSD 249/4885CTSB 317/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | BACE1 1/4885CTSD 96/4885CTSB 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.